Monitoring osteoporosis therapy

Clinical Chemistry

Volumn 51, Issue 12, 2005, Pages 2227-2228

  Kleerekoper, Michael ^a   Camacho, Pauline ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT 5B ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEOXYPYRIDINOLINE; ESTROGEN; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PYRIDINOLINE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

BONE MASS; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; EDITORIAL; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BONE DENSITY; DRUG MONITORING; HUMANS; OSTEOPOROSIS;

EID: 28044469842     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.058958     Document Type: Editorial

References (11)

1. US Department of Health an Human Services. Bone health and osteoporosis: a report of the Surgeon General (2004). http://www.surgeongeneral. gov/library/bonehealth/content.html (accessed September 2005).
2. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al.; Osteoporotic Fractures Research Group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003;18:1947-54.
3. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004;34:195-202.
4. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367-73.
5. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Potential risk factors for development of postmenopausal osteoporosis-examined over a 12-year period. Osteoporos Int 1991;1:95-102.
6. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-8.
7. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.
8. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al.; Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-8.
9. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344-51.
10. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401.
11. Välimäki MJ, Tähtelä R. Serum tartrate-resistant acid phosphatase 5B or amino-terminal propeptide of type I procollagen for monitoring bisphosphonate therapy in postmenopausal osteoporosis? Clin Chem 2005;51: 2382-5.